Is PET-Based Treatment Planning the New Standard in Modern Radiotherapy? The Head and Neck Paradigm

Seminars in Radiation Oncology

Volumn 16, Issue 4, 2006, Pages 232-238

  Grégoire, Vincent ^a   Bol, Anne ^a   Geets, Xavier ^a   Lee, John ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

FDG; head and neck; molecular imaging; PET; radiotherapy; target volume; volume segmentation

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; IMAGING; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING; UTERINE CERVIX CANCER;

HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL;

EID: 33748923665     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2006.04.006     Document Type: Article

References (63)

1. Bernier J., Hall E.J., and Giaccia A. Radiation oncology: A century of achievements. Nat Rev Cancer 4 (2004) 737-747
2. Moran J.M., Elshaikh M.A., and Lawrence T.S. Radiotherapy: What can be achieved by technical improvements in dose delivery?. Lancet Oncol 6 (2005) 51-58
3. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
4. Braams J.W., Pruim J., Freling N.J., et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 36 (1995) 211-216
5. Laubenbacher C., Saumweber D., Wagner-Manslau C., et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 36 (1995) 1747-1757
6. McGuirt W.F., Williams III D.W., Keyes Jr. J.W., et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 105 (1995) 373-375
7. Benchaou M., Lehmann W., Slosman D.O., et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol 116 (1996) 332-335
8. Myers L.L., and Wax M.K. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol 27 (1998) 342-347
9. Stokkel M.P., ten Broek F.W., Hordijk G.J., et al. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18-fluorodeoxyglucose positron emission tomography. Ann Surg 231 (2000) 229-234
10. Stuckensen T., Kovacs A.F., Adams S., et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: A prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 28 (2000) 319-324
11. Dammann F., Horger M., Mueller-Berg M., et al. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol 184 (2005) 1326-1331
12. Shah J.P. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 160 (1990) 405-409
13. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343 (2000) 254-261
14. Poncelet A.J., Lonneux M., Coche E., et al., Groupe d'Oncologie Thoracique des Cliniques Saint-Luc. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 20 (2001) 468-474
15. Kernstine K.H., Mclaughlin K.A., Menda Y., et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?. Ann Thorac Surg 73 (2002) 394-401
16. Gould M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med 139 (2003) 879-892
17. Schrevens L., Lorent N., Dooms C., et al. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 9 (2004) 633-643
18. van Westreenen H.L., Westerterp M., Bossuyt P.M., et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
19. Vrieze O., Haustermans K., De Wever W., et al. Is there a role of FDG-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol 73 (2004) 269-275
20. Reinhardt M.J., Ehritt-Braun C., Vogelgesang D., et al. Metastatic lymph nodes in patients with cervical cancer: Detection with MR imaging and FDG PET. Radiology 218 (2001) 776-782
21. Rose P.G., Adler L.P., Rodriguez M., et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: A surgicopathologic study. J Clin Oncol 17 (1999) 41-45
22. Sugawara Y., Eisbruch A., Kosuda S., et al. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 40 (1999) 1125-1131
23. Antoch G., Saoudi N., Kuehl H., et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22 (2004) 4357-4368
24. Bar-Shalom R., Yefremov N., Guralnik L., et al. Clinical performance of PET/CT in evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med 44 (2003) 1200-1209
25. Yeung H.W., Schoder H., Smith A., et al. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients. Mol Imaging Biol 7 (2005) 229-235
26. Ciernik I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57 (2003) 853-863
27. Wienhard K., Dahlbom M., Eriksson L., et al. The ECAT EXACT HR. Performance of a new high resolution positron scanner. J Comput Assist Tomogr 18 (1994) 110-118
28. Tarantola G., Zito F., and Gerundini P. PET instrumentation and reconstruction algorithms in whole-body applications. J Nucl Med 44 (2003) 756-769
29. Brix G., Zaers J., Adam L.-E., et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med 38 (1997) 1614-1623
30. Alessio A., and Kinahan P. PET image reconstruction. In: Henkin R., Bova D., Dillehay G.L., et al. (Eds). Nuclear Medicine. (ed 2). (2006), Elsevier, New York, NY
31. Gonzales R.C., and Wood R.E. Digital Image Processing. (ed 2). (1992), Addison-Wesley Publishing Company, Reading, MA
32. Elad M. On the origin of the bilateral filter and ways to improve it. IEEE Trans Image Process 10 (2002) 1141-1151
33. Nagayoshi M., Murase K., Fujino K., et al. Usefulness of noise adaptive non-linear Gaussian filter in FDG-PET study. Ann Nucl Med 19 (2005) 469-477
34. Carasso A.S. Linear and nonlinear image deblurring: A documented study. SIAM J Numer Anal 36 (1999) 1659-1689
35. Nishioka T., Shiga T., Shirato H., et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 53 (2002) 1051-1057
36. Paulino A.C., Koshy M., Howell R., et al. Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 61 (2005) 1385-1392
37. Gregoire V., Daisne J.F., and Geets X. Comparison of CT- and FDG-PET-defined GT: In regard to Paulino et al. (Int J Radiat Oncol Biol Phys 2005;61:1385-1392). Int J Radiat Oncol Biol Phys 63 (2005) 308-309
38. Daisne J.F., Sibomana M., Bol A., et al. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: Influence of reconstruction algorithms. Radiother Oncol 69 (2003) 247-250
39. Daisne J.F., Gregoire V., Duprez T., et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233 (2004) 93-100
40. Nestle U., kremp S., Kirsch C.M., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46 (2005) 1342-1348
41. Black Q.C., Grills I.S., Kestin L.L., et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 60 (2004) 1272-1282
42. Geets X., Lee J., Lonneux M., et al. Re-assessment of tumor volume during radiotherapy with anatomic and functional imaging in head and neck cancers. Radiother Oncol 78 (2006) S59 (suppl 1) 2006
43. Kubota R., Kubota K., Yamada S., et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 35 (1994) 104-112
44. Anzai Y., Minoshima S., Wolf G.T., et al. Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. Radiology 212 (1999) 285-290
45. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
46. Borbath I., Gregoire V., Bergstrom M., et al. Use of 5-[(76)Br]bromo-2′-fluoro-2′-deoxyuridine as a ligand for tumour proliferation: Validation in an animal tumour model. Eur J Nucl Med Mol Imaging 29 (2002) 19-27
47. Gronroos T., Bentzen L., Marjamaki P., et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 513-520
48. Mahy P., De Bast M., Leveque P.H., et al. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3. Eur J Nucl Med Mol Imaging 31 (2004) 1263-1272
49. Mishani E., Abourbeh G., Jacobson O., et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 48 (2005) 5337-5348
50. Ling C.C., Humm J., Larson S., et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47 (2000) 551-560
51. Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
52. De Ruysscher D., Wanders S., Minken A., et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Radiother Oncol 77 (2005) 5-10
53. Douglas J.G., Stelzer K.J., Mankoff D.A., et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: Clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 64 (2006) 886-891
54. Moureau-Zabotto L., Touboul E., Lerouge D., et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 63 (2005) 340-345
55. Mutic S., Malyapa R.S., Grigsby P.W., et al. PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-A dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys 55 (2003) 28-35
56. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
57. Bussink J., Kaanders J.H., Rijken P.F., et al. Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts. Br J Cancer 77 (1998) 57-64
58. Humm J.L., Lee J., O'Donoghue J.A., et al. Changes in FDG tumor uptake during and after fractionated radiation therapy in a rodent tumor xenograft. Clin Positron Imaging 2 (1999) 289-296
59. Haustermans K., Vanuytsel L., Geboes K., et al. In vivo cell kinetic measurements in human oesophageal cancer: What can be learned from multiple biopsies?. Eur J Cancer 30A (1994) 1787-1791
60. Geets X., Daisne J.F., Tomsej M., et al. Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: Comparison between pre- and per-treatment studies. Radiother Oncol 78 (2006) 291-297
61. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6 (2005) 112-117
62. Alber M., Paulsen F., Eschmann S.M., et al. On biologically conformal boost dose optimization. Phys Med Biol 48 (2003) N31-N35
63. Barker Jr. J.L., Garden A.S., Ang K.K., et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 59 (2004) 960-970